证券代码：688075 证券简称：安旭生物 公告编号：2026-006 本议案无需提交公司股东会审议。 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第三届董事 会第四次会议通知于 2026 年 3 月 24 日以邮件方式发出送达全体董事，会议于 2026 年 3 月 30 日以现场结合通讯表决方式召开，会议由公司董事长凌世生先生主持， 会议应到董事 7 人，实到董事 7 人。本次会议的召集、召开符合《中华人民共和国 公司法》等法律、法规、规章、规范性文件和《公司章程》的有关规定，会议形成 的决议合法、有效。 二、董事会会议审议情况 （一） 审议通过《关于以集中竞价交易方式回购股份方案的议案》 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《安 旭生物关于以集中竞价交易方式回购股份方案的公告》 （公告编号：2026-007）。 表决结果：同意 7 票，反对 0 票，弃权 0 ...

证券代码：688075 证券简称：安旭生物 公告编号：2026-007 杭州安旭生物科技股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事、高管、控股股东、实际控制人及一致行动人、持股 5%以上的股 东未来3个月、未来6个月暂无明确的减持计划；如上述人员后续有相关减持股 份计划， 公司将按照法律、法规、规范性文件的要求及时履行信息披露义务。 ●相关风险提示： 1、本次回购股份存在回购期限内公司股票价格持续超出回购方案披露的价格 上限，导致回购方案无法顺利实施的风险； 2、若公司在实施回购股份期间，受外部环境变化、临时经营需要等因素影 响，致使本次回购股份所需资金未能筹措到位，可能存在回购方案无法实施或 者部分实施的风险； 3、若发生对公司股票交易价格产生重大影响的重大事项，或公司生产经营、 财务情况、外部客观情况发生重大变化，或其他导致董事会终止本次回购方案 的事项发生，则存在回购方案无法顺利实施或者根据相关规定变更或终止本次 回购方案的风险； ...

证券代码：688075 证券简称：安旭生物 公告编号：2026-008 杭州安旭生物科技股份有限公司 关于变更公司财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》《公司章程》的相关规定，经公司总经理提名并经董事会提 名委员会、董事会审计委员会对财务总监任职资格审查通过，2026 年 3 月 30 日， 公司召开第三届董事会第四次会议，会议审议通过了《关于变更公司财务总监的 议案》，公司董事会认为林晓女士拥有丰富的财务管理经验，具备担任公司财务 总监的能力，同意聘任林晓女士为公司财务总监（简历详见附件），任期自本次 董事会审议通过之日起至第三届董事会届满之日止。 林晓女士具备相应的任职资格，能够胜任财务总监相关职责的工作，不存在 《公司法》规定的不能担任公司高级管理人员、财务负责人的情形，未受过中国 证监会、证券交易所及其他有关部门的处罚或惩戒，也不存在其他不得担任上市 公司高级管理人员、财务负责人之情形。本次财务总监的聘任程序符合《公司法》 等有关法律法规和《公司章程》的规定。 特此公告。 杭州安 ...

证券代码：688075 证券简称：安旭生物 公告编号：2026-005 杭州安旭生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，杭州安旭生物科技股份有限公司（以下简称"公司"） 股东马华祥持有公司股份 14,773,360 股，占减持计划实施前公司总股本的 11.62%。上述股份为公司首次公开发行前取得的股份以及公司实施资本公积金转 增股本取得的股份，并已于 2024 年 11 月 18 日起解除限售上市流通。 减持计划的实施结果情况 公司于 2025 年 11 月 19 日在上海证券交易所网站（www.sse.com.cn）披露 了《杭州安旭生物科技股份有限公司股东减持股份计划公告》（公告编号： 2025-032）。股东马华祥因自身资金需求，拟通过集中竞价交易方式减持其所持 有的公司股份数量合计不超过 1,200,000 股，即不超过公司总股本的 0.94%，且 在任意连续 90 个自然日内，减持的股份总数不 ...

Financial Performance Summary - In 2025, the company achieved operating revenue of 453.58 million yuan, a decrease of 16.11% compared to the previous year [2] - The net profit attributable to the parent company was 73.38 million yuan, down 61.84% year-on-year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 15.37 million yuan, a decline of 59.44% from the previous year [2] - Total assets at the end of the reporting period were 5.61 billion yuan, a decrease of 2.72% from the end of the previous year [2] - Equity attributable to the parent company was 5.17 billion yuan, down 0.64% from the previous year [2] Operational and Strategic Developments - The company focused on stable development of its main business, integrating existing high-quality technology resources, and increasing strategic investment in new technology platforms [2] - The company made significant progress in domestic and international product registration and certification, reinforcing its long-term competitive advantage in the industry [2] - The company implemented lean management to enhance operational efficiency and cost control, resulting in notable improvements in quality and efficiency [2] - The company expanded its overseas branch layout, achieving positive progress in international market development, which increased sales expenses but opened up future growth opportunities [2] Factors Affecting Financial Results - The decline in net profit was attributed to multiple external factors, including increased tariffs imposed by the U.S. government, which led to reduced orders in certain regional markets and increased operating costs [3] - Other contributing factors included exchange rate fluctuations resulting in foreign exchange losses, decreased interest income, and asset depreciation [3] - Significant declines in operating profit, total profit, and basic earnings per share were noted, with decreases of 66.73%, 64.34%, and 61.59% respectively, primarily due to the impact of tariffs and increased expenses from overseas market expansion [4]

Core Viewpoint - Anxu Bio (688075.SH) reported a decline in both revenue and net profit for the fiscal year 2025, indicating challenges in maintaining growth amidst a competitive landscape [1] Financial Performance - The company achieved operating revenue of 453.58 million yuan, a decrease of 16.11% compared to the same period last year [1] - The net profit attributable to the parent company was 73.38 million yuan, down 61.84% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 15.37 million yuan, reflecting a decline of 59.44% year-on-year [1] Strategic Initiatives - The company focused on steady development of its core business, integrating existing high-quality technological resources [1] - There was a continuous strategic investment in new technology platforms, aimed at enhancing long-term competitive advantages in the industry [1] - The company advanced its operational upgrade centered on lean management, significantly improving operational efficiency and cost control [1] International Expansion - The company increased its efforts in establishing overseas branches, achieving positive progress in expanding its international market presence [1] - Correspondingly, sales expenses increased, which is expected to open up space for sustained growth in the future [1]

Core Viewpoint - Anxu Bio's 2025 annual performance report indicates a significant decline in revenue and profits, primarily due to increased tariffs from the U.S., rising operating costs, and foreign exchange losses [1] Financial Performance - Total operating revenue for 2025 was 453,575,110.94 yuan, a year-on-year decrease of 16.11% [1] - Operating profit was 69,056,267.09 yuan, down 66.73% year-on-year [1] - Net profit attributable to shareholders was 73,382,112.04 yuan, reflecting a 61.84% decline compared to the previous year [1] Asset and Equity Status - Total assets at the end of the reporting period were 5,612,123,002.48 yuan, a decrease of 2.72% from the end of the previous year [1] - Equity attributable to shareholders was 5,170,052,841.50 yuan, down 0.64% from the end of the previous year [1]

Group 1 - The company announced a projected revenue of 453,575,110.94 yuan for the year 2025 [2] - The net profit attributable to the parent company's owners is expected to be 73,382,112.04 yuan in 2025 [2]

Core Viewpoint - The company, Anxu Biotech, is set to release its 2025 annual report, revealing a significant decline in net profit by 61.84% year-on-year, amounting to 73.38 million yuan [1]. Financial Performance Summary - The company reported an operating revenue of 453.58 million yuan, a decrease of 16.11% compared to the previous year [2]. - The net profit attributable to the parent company was 73.38 million yuan, down 61.84% year-on-year [2]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 15.37 million yuan, reflecting a decline of 59.44% [2]. - Total assets at the end of the reporting period were 5.61 billion yuan, a decrease of 2.72% from the end of the previous year [2]. - The equity attributable to the parent company was 5.17 billion yuan, down 0.64% from the end of the previous year [2]. Operational and Strategic Insights - The company aims for stable development in its core business, integrating quality technology resources and increasing strategic investments in new technology platforms [2]. - Efforts to enhance operational efficiency and cost control through lean management have shown significant results [2]. - The company is expanding its international presence, with positive progress in overseas market development, although this has led to increased sales expenses [2]. Factors Affecting Performance - The decline in net profit is attributed to multiple external factors, including increased tariffs imposed by the U.S. government, which reduced orders in certain markets and raised operating costs [3][4]. - Additional factors contributing to the profit decline include exchange rate fluctuations, reduced interest income, and depreciation expenses [3][4]. Business Focus - Anxu Biotech specializes in the research, development, production, and sales of POCT (Point of Care Testing) reagents and instruments [5].

Financial Performance - Total revenue for 2025 was RMB 453.58 million, a decrease of 16.11% compared to RMB 540.70 million in the previous year[4] - Net profit attributable to shareholders was RMB 73.38 million, down 61.84% from RMB 192.30 million year-on-year[4] - The basic earnings per share decreased to RMB 0.58, a decline of 61.59% from RMB 1.51 in the previous year[4] - The return on equity decreased to 1.41%, down 2.31 percentage points from 3.72% in the previous year[4] - The net profit excluding non-recurring gains and losses was RMB 15.37 million, a decrease of 59.44% from RMB 37.90 million year-on-year[4] Assets and Investments - Total assets at the end of the reporting period were RMB 5,612.12 million, a decrease of 2.72% from RMB 5,769.31 million at the beginning of the period[4] - The company has increased its strategic investment in new technology platforms and is advancing product registration and certification domestically and internationally[6] Market and Operational Challenges - The decline in net profit was primarily due to increased tariffs imposed by the U.S. government, leading to reduced orders in certain markets and increased operating costs[7] - The company is expanding its overseas branch layout, which has resulted in increased sales expenses but is expected to open up space for future growth[6] - The company emphasizes the importance of operational upgrades centered on lean management to enhance efficiency and cost control[6]